Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines

This study is currently recruiting participants.
Verified April 2013 by GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: January 7, 2010
Last updated: April 5, 2013
Last verified: April 2013

The purpose of this post-marketing surveillance study is to evaluate the safety of Synflorix™ when administered according to the local Prescribing Information to healthy Filipino infants.

Condition Intervention Phase
Pneumococcal Disease
Biological: Synflorix™
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Post-marketing Surveillance Study of GSK Biologicals' Pneumococcal Conjugate Vaccine, Synflorix, When Administered According to the Local Prescribing Information in Philippines

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Occurrence of grade 3 unsolicited adverse events. [ Time Frame: Within 31 days (Day 0 - Day 30) after each vaccination. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Occurrence of unsolicited adverse events. [ Time Frame: During 31 days (Day 0 - Day 30) follow-up period after each vaccination/vaccine dose. ] [ Designated as safety issue: No ]
  • Occurrence of serious adverse events. [ Time Frame: From the Dose 1 up to study end. ] [ Designated as safety issue: No ]

Estimated Enrollment: 3000
Study Start Date: May 2010
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Synflorix Group
Subjects receiving Synflorix™ according to local Prescribing Information.
Biological: Synflorix™
Intramuscular administration of 1, 2, 3 doses or a booster dose according to local prescribing information


Ages Eligible for Study:   6 Weeks and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.
  • Filipino male or female subjects whose age at the first vaccination with Synflorix is not lesser than 6 weeks of age.
  • For subjects who will receive vaccination on the second dose or third dose onwards, administration of the second dose or third dose of Synflorix as part of the post-marketing surveillance study should be according to the local Prescribing Information. Subjects who will complete their primary vaccination series either starting at first, second or third dose of Synflorix, booster dose will no longer be within the scope of the post-marketing surveillance for these subjects even if return for the booster dose and if they follow up.
  • Subjects will be enrolled in booster dose visit only if this is their first visit or first dose of Synflorix in the post-marketing surveillance. For subjects who will receive Synflorix as a booster dose to a primary vaccination series of a pneumococcal vaccine other than Synflorix, there should be an interval of at least 6 months from the last dose of primary vaccination.
  • Written, signed or thumb-printed informed consent obtained from the parent(s)/guardian(s)/LAR of the child. Where parent(s)/guardian(s) are illiterate, the consent form will be countersigned by a witness.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

  • Acute disease and/or fever at the time of vaccine administration.
  • Fever is defined as temperature >= 37.5°C on axillary, infrared or tympanic setting.
  • Subjects with a minor illness without fever may, be enrolled at the discretion of the investigator.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
  • History of chronic condition(s) requiring treatment such as cancer or autoimmune diseases.
  • Hypersensitivity to latex.
  • Any contraindications as stated in the Prescribing Information.
  Contacts and Locations
Please refer to this study by its identifier: NCT01046097

Contact: US GSK Clinical Trials Call Center 877-379-3718

GSK Investigational Site Recruiting
Quezon City, Philippines, 1113
Contact: US GSK Clinical Trials Call Center    877-379-3718   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466   
GSK Investigational Site Recruiting
Sta. Mesa, Manila, Philippines
Contact: US GSK Clinical Trials Call Center    877-379-3718   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466   
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline Identifier: NCT01046097     History of Changes
Other Study ID Numbers: 113381
Study First Received: January 7, 2010
Last Updated: April 5, 2013
Health Authority: Philippines: Bureau of Food and Drugs

Keywords provided by GlaxoSmithKline:
Pneumococcal vaccine processed this record on April 17, 2014